1. Introduction {#sec1-ijerph-13-00806}
===============

Diabetic retinopathy (DR) is the leading cause of vision loss in adults aged 20--74 years \[[@B1-ijerph-13-00806]\]. With the increasing prevalence of diabetes, the number of instances of DR and vision-threatening DR (VTDR), has been estimated to rise to 191.0 million and 56.3 million, respectively, by 2030 \[[@B2-ijerph-13-00806]\]. DR is a complex trait involving polygenic, metabolic, and environmental influence. Known risk factors---most notably duration of diabetes and glycemic control---explain some, but not all, of the progression of DR \[[@B3-ijerph-13-00806],[@B4-ijerph-13-00806],[@B5-ijerph-13-00806]\]. There are diabetic patients that develop DR despite short durations of diabetes and/or excellent glycemic control, and other diabetic patients who do not develop DR in the face of long-standing diabetes and/or long-term hyperglycemia \[[@B6-ijerph-13-00806]\]. Therefore, given the complexity of the disease, genetic factors may explain some of the variation in the development of DR \[[@B7-ijerph-13-00806]\].

The gene encoding methylenetetrahydrofolate reductase (MTHFR, chromosome 1p36.3), which catalyzes the methylation of homocysteine to methionine \[[@B8-ijerph-13-00806]\], has been widely regarded as a genetic candidate for diabetes mellitus (DM). It has been demonstrated that the single nucleotide polymorphism (SNP) in *MTHFR* gene at nucleotide 677C/T(amino acid 222Ala/Val) can destroy the enzyme activity and cause hyperhomocysteinemia (HHcy) \[[@B9-ijerph-13-00806],[@B10-ijerph-13-00806],[@B11-ijerph-13-00806]\]. Because of such critical functional influence, it is readily postulated that the polymorphism of *MTHFR* 677C/T contributes to the development of DR, and a number of studies have addressed the role of the variation in the complex etiology of DR.

Numerous molecular epidemiological studies have been performed to estimate the relationship between the *MTHFR* 677C/T polymorphism and DR \[[@B12-ijerph-13-00806],[@B13-ijerph-13-00806],[@B14-ijerph-13-00806],[@B15-ijerph-13-00806],[@B16-ijerph-13-00806],[@B17-ijerph-13-00806],[@B18-ijerph-13-00806],[@B19-ijerph-13-00806],[@B20-ijerph-13-00806],[@B21-ijerph-13-00806],[@B22-ijerph-13-00806],[@B23-ijerph-13-00806],[@B24-ijerph-13-00806],[@B25-ijerph-13-00806],[@B26-ijerph-13-00806],[@B27-ijerph-13-00806],[@B28-ijerph-13-00806],[@B29-ijerph-13-00806]\], but the results remain inconclusive. Although several meta-analyses have been published \[[@B30-ijerph-13-00806],[@B31-ijerph-13-00806]\], they still did not reach a consistent conclusion. To better shed light on these conflicting findings, we conducted a comprehensive meta-analysis on 18 published studies from 1996 to 2016, with 1747 diabetic retinopathy cases and 3146 controls relating the variant of the *MTHFR* 677C/T to the risk of developing DR.

2. Methods {#sec2-ijerph-13-00806}
==========

This study was reported according to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for reporting systematic reviews and meta-analyses. Study selection, data extraction, and quality assessment were completed independently by two investigators. Disagreement was resolved through discussion. If the discussion did not lead to a consensus, Professor Wang made the final decision.

2.1. Identification and Eligibility of Relevant Studies {#sec2dot1-ijerph-13-00806}
-------------------------------------------------------

We attempted to include all the studies that determined the genotype distribution of *MTHFR* 677C/T polymorphism in cases of diabetes retinopathy, and (i) in healthy controls or (ii) in diseased controls (subjects with diabetes and free of DR) in the meta-analysis. Cases were type 1 or 2 diabetic subjects with background, simple, advanced, or proliferative DR. The diseased control group consisted of subjects with diabetes and free of diabetic retinopathy disease, i.e., diabetes nephropathy.

We first identified studies by searching the electronic literature PubMed and Embase for relevant reports in English and CNKI for papers in Chinese (from January 1996 to April 2016, using the search terms "(MTHFR or methylenetetrahydrofolate reductase) and (diabetes or diabetic) and (retinopathy) and (gene or polymorphism or allele or genotype or variant or variation or mutation)" \[[@B30-ijerph-13-00806]\]. We chose articles which were conducted among human subjects. Eligible studies were then identified by further searching the studies on the association between *MTHFR* 677C/T polymorphism and diabetic retinopathy risk. We restricted attention to the studies that satisfied all of the following criteria: (1) studies related to the *MTHFR* polymorphism were determined regardless of sample size and study design (case-control, cross-sectional or cohort studies); (2) each genotype frequency was reported; and (3) there was sufficient information for extraction of data. If studies had partly overlapped subjects, only the one with a larger and/or latest sample size was selected for the analysis. Additional studies were identified by hands-on searches from references of original studies or review articles on this topic. According to these criteria, we finally included 18 papers in our meta-analysis.

2.2. Data Extraction and Conversion {#sec2dot2-ijerph-13-00806}
-----------------------------------

Two investigators independently extracted data and reached a consensus on all of the items. Data extracted from these articles included the first author's name, publication year, study design, ethnicity of population, DM type, clinical characteristics, and the number of cases and controls for *MTHFR* C677T genotypes. The frequencies of the alleles and the genotypic distributions were extracted or calculated for both cases and controls. We merged the original data into the control group or case group if the study did not provide corresponding data. For some studies without sufficient information for extraction of data, we tried to contact with the studies' authors by sending emails from their articles to request missing data. In addition, it was tested whether the distribution of genotypes in the controls was consistent with Hardy--Weinberg equilibrium (HWE) for each study, and the frequency of the minor allele for *MTHFR* 677C/T polymorphism was calculated.

2.3. Quality Assessment and Study Stratification {#sec2dot3-ijerph-13-00806}
------------------------------------------------

We used the Newcastle--Ottawa scale (NOS) method to assess the observational studies that were included. The NOS is composed of 3 parts (8 entries): selection, comparability, and exposure. A quality item is given only one star for the study in selection and exposure, and a quality item is given at most two stars for the study in comparability. It is a semi-quantitative scale, and a score of 0--9 stars is assigned to each study. Studies whose scores were more than 6 stars were considered to be of relatively high quality \[[@B32-ijerph-13-00806]\]. The scores of included studies are shown in [Table 1](#ijerph-13-00806-t001){ref-type="table"}.

2.4. Meta-Analysis {#sec2dot4-ijerph-13-00806}
------------------

Our meta-analysis evaluated the relationship between the *MTHFR* 677C/T polymorphism and the risk of DR for each study by odds ratio (OR) with 95% confidence intervals (95% CI). For all studies, we calculated the ORs for the: (i) separate pairwise comparisons; (ii) allele contrast; (iii) recessive model; and (iv) dominant model. In addition, we conducted stratification analysis by ethnicity and DM type. A sensitivity analysis, which examines the effect of excluding specific studies, was also performed \[[@B33-ijerph-13-00806]\]. Our meta-analysis was subjected to sensitivity analysis for studies with the controls not in HWE (*p* \< 0.05).

The χ^2^-based Q statistic test was used to assess the heterogeneity, and it was considered significant for *p* \< 0.05. Heterogeneity was quantified with the *I*^2^ metric, which is independent of the number of studies in the meta-analysis. *I*^2^ takes values between 0% and 100%, with higher values denoting greater degree of heterogeneity (*I*^2^ \> 50% was considered significant) \[[@B34-ijerph-13-00806]\]. We used the fixed-effects model and the random-effects model based on the Mantel--Haenszel method and the DerSimonian and Laird method, respectively, to combine values from each of the studies. When the effects were assumed to be heterogeneous, the random-effects model was used; otherwise, the fix-effects model was more appropriate \[[@B35-ijerph-13-00806]\]. In addition, we further conducted meta-regression analyses to estimate the source of heterogeneity. Publication bias was assessed according to the Begg adjusted rank correlation test and the Egger regression asymmetry test \[[@B36-ijerph-13-00806],[@B37-ijerph-13-00806]\]. All analysis was done using the Stata software (v.12.1) (StataCorp LP, College Station, TX, USA). All the *p* values were two-sided.

3. Results {#sec3-ijerph-13-00806}
==========

3.1. Literature Search {#sec3dot1-ijerph-13-00806}
----------------------

The study selection process is shown in [Figure 1](#ijerph-13-00806-f001){ref-type="fig"}. A total of 97 articles (PubMed 35, Embase 46 and CNKI 16) were identified from the databases, and 25 duplicates were excluded using EndNote (X7). In addition, 52 articles were excluded based on a review of the titles and abstracts, and 20 full-text articles were assessed for eligibility; 2 articles were excluded due to could not provide each genotype frequency or other sufficient information for extraction of data. Finally, a total of 18 \[[@B12-ijerph-13-00806],[@B13-ijerph-13-00806],[@B14-ijerph-13-00806],[@B15-ijerph-13-00806],[@B16-ijerph-13-00806],[@B17-ijerph-13-00806],[@B18-ijerph-13-00806],[@B19-ijerph-13-00806],[@B20-ijerph-13-00806],[@B21-ijerph-13-00806],[@B22-ijerph-13-00806],[@B23-ijerph-13-00806],[@B24-ijerph-13-00806],[@B25-ijerph-13-00806],[@B26-ijerph-13-00806],[@B27-ijerph-13-00806],[@B28-ijerph-13-00806],[@B29-ijerph-13-00806]\] articles were included in this meta-analysis.

3.2. Eligible Studies and Study Characteristics {#sec3dot2-ijerph-13-00806}
-----------------------------------------------

The selected study baseline characteristics from the qualified studies included in the meta-analysis are provided in [Table 1](#ijerph-13-00806-t001){ref-type="table"} and the frequencies on *MTHFR* C677T polymorphism allele/genotype prevalence are shown in [Table 2](#ijerph-13-00806-t002){ref-type="table"}. Of 18 studies, 12 studies (9 Asian, 2 Caucasian, and 1 American population) were based on type 2 DM (T2DM) including participants (case group; control group), and 6 studies (3 Caucasian and 3 Asian) was based onnon-T2DM (2 studies (\[[@B12-ijerph-13-00806],[@B14-ijerph-13-00806]\]) with type 1 DM (T1DM), 2 (\[[@B21-ijerph-13-00806],[@B24-ijerph-13-00806]\]) with un-defined DM type, and 2 (\[[@B23-ijerph-13-00806],[@B28-ijerph-13-00806]\]) involved both T1DM and T2DM) including participants (case group; control group). Ten studies were case-control study design and 8 studies were cross-sectional study design.

3.3. Summary Statistics {#sec3dot3-ijerph-13-00806}
-----------------------

Data from 18 articles that investigated the association between the *MTHFR* 677C/T polymorphism and DR risk were included in the meta-analysis. The overall frequency (%) of minor D allele frequency (MAF) was 0.44/0.33 for cases and controls. The frequency of the MAF for each individual study polymorphism for controls is given in [Table 1](#ijerph-13-00806-t001){ref-type="table"}. All studies indicated that the distribution of genotypes in the controls was consistent with Hardy--Weinberg equilibrium except for 3 studies (\[[@B19-ijerph-13-00806],[@B22-ijerph-13-00806],[@B24-ijerph-13-00806]\]), indicating genotyping errors and/or population stratification \[[@B33-ijerph-13-00806]\]; therefore, a sensitivity analysis was performed by excluding these studies.

3.4. Main Results, Stratification, and Sensitivity Analyses {#sec3dot4-ijerph-13-00806}
-----------------------------------------------------------

The estimation results of the relationship of *MTHFR* 677C/T polymorphism with DR are presented in [Table 3](#ijerph-13-00806-t003){ref-type="table"}. [Figure 2](#ijerph-13-00806-f002){ref-type="fig"} shows the overall results for the association between the polymorphism and the risk of DR (in dominant model).

As it shown in [Table 3](#ijerph-13-00806-t003){ref-type="table"}, the overall analysis found a significant association between the *MTHFR* 677C/T polymorphism and the risk of DR for all genetic models (CT vs. CC: OR = 1.46, 95% CI: 1.15--1.86; TT vs. CC:OR = 2.45, 95% CI: 1.66--3.60; Allele contrast: OR = 1.52, 95% CI: 1.26--1.84; recessive model: OR = 1.67, 95% CI: 1.19--2.40 and dominant model: OR = 1.71, 95% CI: 1.28--2.28, respectively).

In stratified analysis by ethnicity and DM type, we further detected that the Asian group, T2DM group showed significant associations for all genetic models (CT vs. CC: OR = 1.71, 95% CI: 1.22--2.39 for Asian group, OR = 1.50, 95% CI: 1.08--2.09 for T2DM group, respectively; TT vs. CC:OR = 2.97, 95% CI: 2.06--4.29 for Asian group, OR = 2.68, 95% CI: 1.74--4.13 for T2DM group, respectively; Allele contrast: OR = 1.75, 95% CI: 1.42--2.18 for Asian group, OR = 1.59, 95% CI: 1.26--2.01 for T2DM group, respectively; recessive model: OR = 2.16, 95% CI: 1.75--2.65 for Asian group, OR = 2.05, 95% CI: 1.47--2.84 for T2DM group, respectively and dominant model: OR = 1.98, 95% CI: 1.42--2.76 for Asian group, OR = 1.72, 95% CI: 1.23--2.42 for T2DM group, respectively). In addition, we further found significant associations for all genetic models in both Asian group with T2DM and non-T2DM (See [Table 3](#ijerph-13-00806-t003){ref-type="table"}). However, we did not find any significant effects for different genetic models in other subgroups. Further sensitivity analysis for HWE almost did not alter the pattern of results in both overall analysis and subgroup analysis (See [Table 3](#ijerph-13-00806-t003){ref-type="table"}).

3.5. Source of Heterogeneity and Publication Bias {#sec3dot5-ijerph-13-00806}
-------------------------------------------------

From [Table 3](#ijerph-13-00806-t003){ref-type="table"}, we found that the heterogeneity between studies was observed in overall comparisons as well as subgroup analyses. We estimated the source of heterogeneity in dominant genetic models of the variant allele by ethnicity (Asian or non-Asian), DM type (T2DM or non-T2DM), HWE (in HWE or not), and study design (case-control or cross-sectional design) by meta-regression analyses. It revealed that DM type and HWE factors could not significantly influence between-study heterogeneity in genetic model for the polymorphism *MTHFR* 677C/T: DM type (*p* = 0.36) and HWE (*p* = 0.06). However, we found that ethnicity and study design factors might be the source of heterogeneity between studies: ethnicity (*p* = 0.03 and contributed 26.8% source of heterogeneity) and study design (*p* = 0.01 and contributed 52.1% source of heterogeneity). In addition, we further found that study design might be the major source of heterogeneity between studies for the Asian DM group (*p* = 0.001 and contributed 100% source of heterogeneity).

The potential presence of publication bias was estimated by using a funnel plot by evaluating log--odds ratio for the genotype TT + CT versus CC against the reciprocal of its standard error ([Figure 3](#ijerph-13-00806-f003){ref-type="fig"}). As is shown, we failed to observe any significant funnel asymmetry which could indicate publication bias. We further conducted the Egger regression asymmetry test and the Begg adjusted rank correlation tests to estimate the publication bias of included literatures in the meta-analysis. As shown in [Table 4](#ijerph-13-00806-t004){ref-type="table"}, no publication bias was found for the polymorphism and risk of DR in both dominant and recessive genetic models.

4. Discussion {#sec4-ijerph-13-00806}
=============

The common environmental risk factors of DR include hyperglycemia, hypertension, hyperlipidemia, obesity, duration of diabetes, puberty, and pregnancy \[[@B2-ijerph-13-00806]\]. However, despite having a long-term hyperglycemia, we often found that some diabetics develop retinopathy, whereas others do not. Because such known environmental factors do not fully explain this, researchers have sought the answer in genetic factors. The enzyme MTHFR methylates homocysteine to generate methionine, and its dysfunction can lead to HHcy \[[@B38-ijerph-13-00806]\]. Studies reported that HHcy induces endothelial dysfunction and arterial stiffness \[[@B39-ijerph-13-00806]\], and has also been associated with atherosclerosis \[[@B40-ijerph-13-00806]\] and retinopathy in both T1DM and T2DM patients \[[@B41-ijerph-13-00806],[@B42-ijerph-13-00806]\]. The *MTHFR* C677T polymorphism leads to an Ala222Val substitution in the N-terminal catalytic domain of the enzyme, which reduces enzyme activity \[[@B43-ijerph-13-00806],[@B44-ijerph-13-00806],[@B45-ijerph-13-00806]\]. In addition, several recent genome-wide association studies (GWAS) have confirmed the association between *MTHFR* C677T genotype and homocysteine levels in healthy populations \[[@B46-ijerph-13-00806],[@B47-ijerph-13-00806]\]. Numerous investigations into the potential role of *MTHFR* as a susceptibility gene for DR have been conducted over the past decades, with controversial results. Early meta-analyses attempted to reconcile these findings, but attempts to draw definite conclusions have been hindered by limited data, particularly when examining specific patient subgroups and increased relative studies \[[@B30-ijerph-13-00806],[@B31-ijerph-13-00806]\].

In the current meta-analysis, the effect of separate pairwise comparisons, allele contrast, and the effects of the dominant and recessive genetic models were estimated. Subgroup analysis by ethnicity and DM type, and sensitivity for studies not in HWE, were performed. In addition, we further evaluated the source of heterogeneity and publication bias of included literatures. It is worth mentioning that we found study design might be the major source of heterogeneity between studies. To provide better power to detect smaller effect sizes, studies related to the *MTHFR* polymorphism were determined regardless of sample size and study design (case-control, cross-sectional, or cohort studies), however, different study designs may generate potential effects on the meta-analysis. For example, the cohort study design may obtain a much more powerful research conclusion than the case-control study design, and the cross-sectional study design could obtain less powerful research conclusion than the case-control study design. Therefore, the overall effect of all studies with different study designs might be deviated from the real effect, to some extent.

Our meta-analysis obtained several critical different conclusions from the previous reports \[[@B30-ijerph-13-00806],[@B31-ijerph-13-00806]\]. In Zintzaras et al. \[[@B31-ijerph-13-00806]\] report, they just included 5 studies with 435 DR cases and 620 controls, which provides relatively poor power to detect smaller effect sizes. In addition, although they found a marginal association between C677T and the risk of developing DR, the results of overall analysis were less significant after conducting sensitivity analysis by excluding the study with the control not in HWE. Niu et al. \[[@B30-ijerph-13-00806]\] just performed the meta-analysis with 8 studies including 1599 subjects and they did not observe significant association with DR in heterozygous genotypic comparison (CT vs. CC) or in dominant model. In addition, they did not perform meta-regression analysis to identify the sources of between-study heterogeneity and found publication bias for comparison. However, from the present meta-analysis of 18 studies---reported from 1996 to 2016 and comprising 4893 subjects---we not only found the main effects for *MTHFR* C677T polymorphism on DR risk with all studies in all genetic models, without any publication bias, but further sensitivity analysis for HWE also did not alter the pattern of results in the overall analysis. From the stratification analysis by ethnicity and DM type, we also found that the *MTHFR* C677T polymorphism was significantly associated with DR risk in T2DM and Asian group, especially in Asian group with T2DM and non-T2DM.These findings may indicate that genetic factors may have more impact on Asian population.

We conducted a comprehensive meta-analysis on 18 published studies with 1747 DR cases and 3146 controls relating to the mutation of the *MTHFR* C677T to the risk of DR, which can provide better power to detect smaller effect sizes. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In order to estimate the power of the study, we used the Power and Precision 4 software to conduct the power calculation by respectively accumulating the frequency of *MTHFR* 677T allele in case (0.44) and control (0.33) groups from all studies, and the result showed the power of our study is over 80%.

Despite the clear strengths of our study, some limitations merit serious consideration. First, non-English/Chinese, non-indexed, and non-published literature were not reviewed in our meta-analysis, thus might introduce some bias \[[@B48-ijerph-13-00806]\]. Second, only the unadjusted pooled ORs were calculated, because data for possible confounding factors that influence the estimates of associations (e.g., age, sex, body mass index) were not provided. Third, sampling variability and stratification in genetic association studies could be a possible confounding factor on the role of genetic markers. In addition, the risk effect may depend on the interaction with other risk factors: diabetes duration, HbA~1c~, blood pressure, total serum cholesterol, control of diabetes, and body mass index, all of which modulate the development of DR \[[@B49-ijerph-13-00806]\]. Furthermore, small numbers of individuals and inadequate information of lifestyle factors and dietary intake by the published studies limited our statistic power to fully investigate the gene-environment interactions \[[@B35-ijerph-13-00806]\]. Therefore, further well-designed large studies, particularly referring to GWAS and gene-environment interactions are warranted to confirm the real contribution of these polymorphisms to DR susceptibility and might further elucidate the genetics of DR.

Although there are several previous GWAS relevant to DR \[[@B50-ijerph-13-00806],[@B51-ijerph-13-00806],[@B52-ijerph-13-00806],[@B53-ijerph-13-00806]\], the limitations in GWAS studies are still inconsistency and low reproducibility in different populations \[[@B2-ijerph-13-00806]\]. Several reasons may explain this \[[@B7-ijerph-13-00806]\]: (i) since the genetic effects of DR might be much modest than other diseases, it requires large sample sizes to identify the real role of genetic factors using GWAS, however, the sample sizes of previous studies on DR GWAS studies were relatively modest; (ii) the diagnosis of DR is clinically complicated with different types of DM, a case with slight retinopathic changes may not be assigned as a DR case, but some of the DR GWAS used case definitions that include such patients which may generate the bias. In addition, different population and heterogeneous phenotypes of DR patients, as well as poor characterization of controls, also affect the consistency of GWAS studies. Therefore, it is still very important to conduct the meta-analysis to estimate the variant of the *MTHFR* C677T to the risk of DR.

5. Conclusions {#sec5-ijerph-13-00806}
==============

In summary, our present meta-analysis finds a relationship between DR and *MTHFR* C677T polymorphism, especially in Asian groups. Prospective and additional GWAS are needed to clarify the real role of the *MTHFR* gene in the development of DR.
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###### 

Oddsratios (ORs; log scale) of diabetic retinopathy (DR) associated with *MTHFR* 677C/T polymorphism for dominant genetic model. The graph shows individual and pooled estimates for different ethnic groups (**A** for all studies; **B** for Asian group; **C** for Non-Asian group).
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![Evaluation of publication bias for all studies using funnel plots. No significant funnel asymmetry was observed which could indicate publication bias.](ijerph-13-00806-g003){#ijerph-13-00806-f003}

ijerph-13-00806-t001_Table 1

###### 

Baseline characteristics of qualified studies included in the meta-analysis.

  Author (Ref \*)                                    Year   Ethnicity   Design   Case   Control                                                                                                                                                                                                                   
  -------------------------------------------------- ------ ----------- -------- ------ --------------- ------------- ---------- ------ --------------------------------------------------------------------------------- -------------------------------------------------------- ---------------- ------ ------ ---
  Neugebauer, S. et al. \[[@B12-ijerph-13-00806]\]   1997   Japan       CS       76     55.5 ± 7.9      16.5 ± 5.1    DR         36     50.5 ± 9.7                                                                        11.2 ± 4.2                                               N*CT*DM          0.67   0.26   7
  Fujita, H. et al. \[[@B13-ijerph-13-00806]\]       1999   Japan       CS       105    60±12           NR            PDR + DN   68     62 ± 10                                                                           NR                                                       T2DM             0.14   0.42   6
  Lauszus, F.F. et al. \[[@B14-ijerph-13-00806]\]    2001   Denmark     CS       112    NR              NR            DR         1084   NR                                                                                NR                                                       T1DM             0.53   0.29   5
  Wang, L.Q. et al. \[[@B15-ijerph-13-00806]\]       2001   China       CC       62     62.50 ± 8.08    8.29 ± 6.40   DR         202    59.42 ± 14.87 for T2DM41.83 ± 17.10 for Healthy                                   7.29 ± 5.80 for T2DM                                     Healthy + T2DM   0.73   0.32   8
  Yang, G.Q. et al. \[[@B16-ijerph-13-00806]\]       2001   China       CC       60     50.7 ± 12.1     1 (0.1--4)    DR         231    51.1 ± 12.8 for T2DM with DN63.0 ± 8.8 for T2DM with NCD52.6 ± 14.9 for Healthy   2 (1--4) for T2DM with DN14 (11--18) for T2DM with NCD   Healthy + T2DM   0.73   0.44   8
  Maeda, M. et al. \[[@B17-ijerph-13-00806]\]        2003   Japan       CS       51     NR              NR            DR         105    NR                                                                                NR                                                       T2DM             0.06   0.37   5
  Santos, K.G. et al. \[[@B18-ijerph-13-00806]\]     2003   Brazil      CS       99     NA              NA            DR         111    NA                                                                                NA                                                       T2DM             0.98   0.39   6
  Sun, J. et al. \[[@B19-ijerph-13-00806]\]          2003   China       CC       110    55.6 ± 6.7      \<5           DR         155    54.7 ± 7.1 for NDR42.3 ± 6.1 for Healthy                                          \>10 for NDR                                             T2DM             0.00   0.33   7
  Yoshioka, K. et al. \[[@B20-ijerph-13-00806]\]     2003   Japan       CS       98     NA              NA            DR         268    NA                                                                                NA                                                       T2DM             0.46   0.38   6
  Huang, D.F. et al. \[[@B21-ijerph-13-00806]\]      2005   China       CC       50     NR              NR            DR         47     NR                                                                                NR                                                       Healthy          0.96   0.26   5
  Yi, X.X. et al. \[[@B22-ijerph-13-00806]\]         2005   China       CC       249    56.53 ± 10.45   5.9 ± 4       DR         65     NR                                                                                NR                                                       Healthy          0.01   0.31   5
  Errera, F.I. et al. \[[@B23-ijerph-13-00806]\]     2006   Brazil      CC       141    55.43 ± 15.33   18 ± 8.67     DR         107    66.11 ± 7.06                                                                      NA                                                       Healthy          0.24   0.40   6
  Liu, D.M. et al. \[[@B24-ijerph-13-00806]\]        2006   China       CC       44     51.9 ± 7.5      NR            DR         84     54.0 ± 13.2                                                                       NA                                                       Healthy          0.01   0.29   5
  Maeda, M. et al. \[[@B25-ijerph-13-00806]\]        2008   Japan       CS       75     NA              NA            DR         115    NA                                                                                NA                                                       T2DM             0.06   0.36   5
  Ukinc, K. et al. \[[@B26-ijerph-13-00806]\]        2009   Turkey/     CS       25     NA              NA            DR         27     NA                                                                                NA                                                       T2DM             0.10   0.24   5
  Ren, M. et al. \[[@B27-ijerph-13-00806]\]          2011   China       CC       161    59.95 ± 10.55   11            DR         213    58.52 ± 12.61                                                                     7                                                        T2DM             0.23   0.42   7
  Yigit, S. et al. \[[@B28-ijerph-13-00806]\]        2013   Turkey      CS       81     NA              NA            DR         149    NA                                                                                NA                                                       T1DM + T2DM      0.98   0.24   5
  Simoes, M.J. et al. \[[@B29-ijerph-13-00806]\]     2014   Portugal    CS       148    58.5 ± 8.4      10.5 ± 5.3    PDR        79     61.8 ± 7.8                                                                        8.9 ± 4.8                                                T2DM             0.73   0.24   7

\* The ref was referred to the reference numbers in this study; ^\#^ Hardy--Weinberg equilibrium (HWE) test and ^&^ the minor allele frequency (MAF) were calculated in control group for each study. NR, not reported; NA, not available; CC, case-control; CS, cross-sectional; CH cohort; DR, diabetes retinopathy; PDR, proliferative diabetes retinopathy; NCD: non-complicated; DN, diabetes nephropathy;T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; N*CT*DM, non-insulin dependent diabetes mellitus.

ijerph-13-00806-t002_Table 2

###### 

The frequency of methylenetetrahydrofolate reductase gene (*MTHFR*) C677T polymorphism allele/genotype prevalence.

  Author (Ref)                                       Prevalence of MTHFR C677T Genotype   Prevalence of Allele Frequency                                                 
  -------------------------------------------------- ------------------------------------ -------------------------------- ----- ------ ----- ----- ------ ------ ------ ------
  Neugebauer, S. et al. \[[@B12-ijerph-13-00806]\]   26                                   20                               38    13     12    3     90     53     62     19
  Fujita, H. et al. \[[@B13-ijerph-13-00806]\]       31                                   20                               57    39     17    9     119    79     91     57
  Lauszus, F.F. et al. \[[@B14-ijerph-13-00806]\]    47                                   542                              57    455    8     87    151    1539   73     629
  Wang, L.Q. et al. \[[@B15-ijerph-13-00806]\]       8                                    94                               27    86     27    22    43     274    81     130
  Yang, G.Q. et al. \[[@B16-ijerph-13-00806]\]       8                                    75                               33    111    19    45    49     261    71     201
  Maeda, M. et al. \[[@B17-ijerph-13-00806]\]        18                                   37                               20    58     13    10    56     132    46     78
  Santos, K.G. et al. \[[@B18-ijerph-13-00806]\]     34                                   41                               53    53     12    17    121    135    77     87
  Sun, J. et al. \[[@B19-ijerph-13-00806]\]          33                                   82                               46    45     31    28    112    209    108    101
  Yoshioka, K. et al. \[[@B20-ijerph-13-00806]\]     33                                   100                              50    132    15    36    116    332    80     204
  Huang, D.F. et al. \[[@B21-ijerph-13-00806]\]      17                                   26                               25    18     8     3     59     70     41     24
  Yi, X.X. et al. \[[@B22-ijerph-13-00806]\]         68                                   35                               110   19     71    11    246    89     252    41
  Errera, F.I. et al. \[[@B23-ijerph-13-00806]\]     61                                   36                               66    57     14    14    188    129    94     85
  Liu, D.M. et al. \[[@B24-ijerph-13-00806]\]        18                                   47                               16    25     10    12    52     119    36     49
  Maeda, M. et al. \[[@B25-ijerph-13-00806]\]        31                                   43                               28    62     16    10    90     148    60     82
  Ukinc, K. et al. \[[@B26-ijerph-13-00806]\]        14                                   14                               11    13     0     0     39     41     11     13
  Ren, M. et al. \[[@B27-ijerph-13-00806]\]          26                                   77                               78    95     57    41    130    249    192    177
  Yigit, S. et al. \[[@B28-ijerph-13-00806]\]        38                                   85                               30    55     13    9     106    225    56     73
  Simoes, M.J. et al. \[[@B29-ijerph-13-00806]\]     69                                   45                               60    30     19    4     198    120    98     38
  Total                                              580                                  1419                             805   1366   362   361   1965   4204   1529   2088
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###### 

Summary ORs and heterogeneity results for associations between the *MTHFR* C677T polymorphism and DR.

  Subgroup                  Genetic Model   Studies No (All/Sensitivity)   OR (95% CI)         *p* \*   *I*^2^ (%)          OR ~se~ (95% CI) ^\#^
  ------------------------- --------------- ------------------------------ ------------------- -------- ------------------- -----------------------
  Overall                   CT vs. CC       18/15                          1.46 (1.15--1.86)   0.00     60.0                1.32 (1.02--1.70)
  TT vs. CC                 18/15           2.45 (1.66--3.60)              0.00                69.0     2.27 (1.44--3.58)   
  Allele contrast           18/15           1.52 (1.26--1.84)              0.00                72.4     1.45 (1.17--1.79)   
  Recessive model           18/15           1.67 (1.19--2.40)              0.00                71.9     1.87 (1.32--2.66)   
  Dominant model            18/15           1.71 (1.28--2.28)              0.00                75.3     1.50 (1.13--1.98)   
  Asian                     CT vs. CC       12/9                           1.71 (1.22--2.39)   0.00     64.9                1.52 (1.01--2.30)
  TT vs. CC                 12/9            2.97 (2.06--4.29)              0.02                51.5     3.07 (1.83--5.14)   
  Allele contrast           12/9            1.75 (1.42--2.18)              0.00                67.3     1.69 (1.28--2.24)   
  Recessive model           12/9            2.16 (1.75--2.65)              0.11                35.1     2.34(1.62--3.38)    
  Dominant model            12/9            1.98 (1.42--2.76)              0.00                68.6     1.83 (1.20--2.81)   
  Non-Asian                 CT vs. CC       6/6                            1.15 (0.92--1.45)   0.38     5.4                 1.15 (0.92--1.45)
  TT vs. CC                 6/6             1.33 (0.69--2.54)              0.04                61.4     1.33 (0.69--2.54)   
  Allele contrast           6/6             1.14 (0.89--1.46)              0.07                51.5     1.14 (0.89--1.46)   
  Recessive model           6/6             1.24 (0.69--2.23)              0.05                57.7     1.24 (0.69--2.23)   
  Dominant model            6/6             1.18 (0.95--1.47)              0.21                30.70    1.18 (0.95--1.47)   
  T2DM                      CT vs. CC       12/10                          1.50 (1.08--2.09)   0.00     66.5                1.32 (0.93--1.86)
  TT vs. CC                 12/10           2.68 (1.74--4.13)              0.00                66.2     2.61 (1.50--4.53)   
  Allele contrast           12/10           1.59 (1.26--2.01)              0.00                74.0     1.49 (1.14--1.96)   
  Recessive model           12/10           2.05 (1.47--2.84)              0.01                56.9     2.10 (1.38--3.17)   
  Dominant model            12/10           1.72 (1.23--2.42)              0.00                72.1     1.54 (1.06--2.24)   
  Non-T2DM                  CT vs. CC       6/5                            1.30 (1.02--1.66)   0.12     43.5                1.32 (0.89--1.97)
  TT vs. CC                 6/5             1.75 (0.93--3.27)              0.05                55.9     1.70 (0.80--3.63)   
  Allele contrast           6/5             1.38 (1.02--1.88)              0.02                64.5     1.34 (0.95--1.91)   
  Recessive model           6/5             1.38 (0.96--2.00)              0.14                39.5     1.32 (0.89--1.97)   
  Dominant model            6/5             1.46 (1.00--2.13)              0.04                57.4     1.42 (0.92--2.19)   
  Asian with T2DM           CT vs. CC       9/7                            1.64 (1.07--2.50)   0.00     73.8                1.40 (0.86--2.29)
  TT vs. CC                 9/7             3.00 (1.92--4.68)              0.01                63.8     2.99 (1.63--5.50)   
  Allele contrast           9/7             1.73 (1.33--2.26)              0.00                76.0     1.64 (1.17--2.29)   
  Recessive model           9/7             2.21 (1.59--3.06)              0.03                51.9     2.33 (1.52--3.57)   
  Dominant model            9/7             1.94 (1.27--2.94)              0.00                76.7     1.72 (1.03--2.89)   
  Asian with Non-T2DM       CT vs. CC       3/2                            1.99 (1.22--3.25)   0.87     0.0                 2.19 (1.19--4.01)
  TT vs. CC                 3/2             2.80 (1.39--5.66)              0.77                0.0      3.50 (1.28--9.62)   
  Allele contrast           3/2             1.86 (1.32--2.60)              0.90                0.0      1.97 (1.28--3.05)   
  Recessive model           3/2             2.06 (1.06--4.02)              0.87                0.0      2.38 (0.91--6.24)   
  Dominant model            3/2             2.17 (1.38--3.42)              0.85                0.0      2.40 (1.35--4.28)   
  Non-Asian with T2DM       CT vs. CC       3/3                            1.20 (0.81--1.76)   0.79     0.0                 1.20 (0.81--1.76)
  TT vs. CC                 3/3             1.54 (0.43--5.46)              0.08                68.2     1.54 (0.43--5.46)   
  Allele contrast           3/3             1.18 (0.90--1.56)              0.25                27.0     1.18 (0.90--1.56)   
  Recessive model           3/3             1.37 (0.39--4.82)              0.06                70.8     1.37 (0.39--4.82)   
  Dominant model            3/3             1.24 (0.86--1.80)              0.58                0.0      1.24 (0.86--1.80)   
  Non-Asian with Non-T2DM   CT vs. CC       3/3                            1.09 (0.69--1.71)   0.09     58.0                1.09 (0.69--1.71)
  TT vs. CC                 3/3             1.24 (0.49--3.14)              0.03                71.9     1.24 (0.49--3.14)   
  Allele contrast           3/3             1.13 (0.76--1.68)              0.02                73.3     1.13 (0.76--1.68)   
  Recessive model           3/3             1.21 (0.54--2.72)              0.05                66.9     1.21 (0.54--2.72)   
  Dominant model            3/3             1.13 (0.69--1.83)              0.05                66.7     1.13 (0.69--1.83)   

^\#^ OR ~se~: Sensitivity analysis OR for HWE; \* Test for heterogeneity: random-effects model was used when *p* value for heterogeneity test \<0.05 and *I*^2^ \> 50%; otherwise, fixed-effects model was used; T2DM, type 2 diabetes mellitus;Non-T2DM, type 1 diabetes mellitus or unknown DM type or mixed DM type; Non-Asian, Caucasian and African-American population.
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###### 

The results of publication bias test by Egger and Begg test.

  Subgroup    Egger Test   Begg Test          
  ----------- ------------ ----------- ------ ------
  all study   0.59         0.48        0.65   0.48
  T2DM        0.91         0.94        0.84   0.64
  Non-T2DM    0.28         0.16        0.06   0.26
  Asian       0.62         0.91        0.63   0.54
  Non-Asian   0.57         0.10        1.00   0.46

T2DM, type 2 diabetes mellitus;Non-T2DM, type 1 diabetes mellitus or unknown DM type or mixed DM type; Non-Asian, Caucasian and African-American population.

[^1]: These authors contributed equally to this work.
